Medicine and Dentistry
Monotherapy
100%
Multiple Myeloma
100%
Daratumumab
100%
Proteasome Inhibitor
57%
Immunomodulatory Drug
57%
Adverse Event
28%
Overall Survival
28%
Monoclonal Antibody
14%
Anemia
14%
Progression Free Survival
14%
Autologous Stem Cell Transplantation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Monotherapy
100%
Daratumumab
100%
Multiple Myeloma
100%
Proteasome Inhibitor
57%
Adverse Event
28%
Overall Survival
28%
Monoclonal Antibody
14%
Anemia
14%
Progression Free Survival
14%
Immunology and Microbiology
Multiple Myeloma
100%
Daratumumab
100%
Immunomodulatory Drug
57%
Proteasome
57%
Overall Survival
28%
Monoclonal Antibody
14%
Progression Free Survival
14%
Autologous Stem Cell Transplantation
14%
CD38
14%
Keyphrases
1-stage
57%
Stringent Complete Response
28%
First Response
14%
Allocation Schedule
14%